Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017

Details for Mechanism ID: 14113
Country/Region: Malawi
Year: 2015
Main Partner: Elizabeth Glaser Pediatric AIDS Foundation
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $4,457,803 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $323,185
Care: TB/HIV (HVTB) $183,764
Care: Pediatric Care and Support (PDCS) $45,000
Laboratory Infrastructure (HLAB) $85,800
Health Systems Strengthening (OHSS) $75,000
Testing: HIV Testing and Counseling (HVCT) $684,670
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $345,106
Treatment: Adult Treatment (HTXS) $2,361,048
Treatment: Pediatric Treatment (PDTX) $354,230
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 88,531
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 24,190
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 69,313
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 69,284
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 228,634
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 212,872
HTS_TST By Test Result: Negative 2016 554,954
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 580,106
HTS_TST Sum of Aggregated Age/Sex <15 2016 138,597
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 441,506
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 580,103
HTS_TST Sum of Test Result disaggregates 2016 580,106
HTS_TST_POS By Test Result: Positive 2016 25,152
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 4,829
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 4,585
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 2,369
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 2,180
PMTCT_ARV Sum of New and Current disaggregates 2016 4,549
PMTCT_EID By infants who received a virologic test within 2 months of birth 2016 1,430
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 2,428
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 3,858
PMTCT_EID Sum of Infant Age disaggregates 2016 3,858
PMTCT_STAT By: Known positives at entry 2016 2,168
PMTCT_STAT By: Number of new positives identified 2016 2,654
PMTCT_STAT Number of new ANC and L&D clients 2016 98,307
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 93,393
PMTCT_STAT Sum of Positives Status disaggregates 2016 4,822
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 1,846
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 1,712
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 88,531
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 86,761
TX_CURR Age/Sex: <1 Female 2016 88
TX_CURR Age/Sex: <1 Male 2016 69
TX_CURR Age/Sex: 1-4 Female 2016 674
TX_CURR Age/Sex: 1-4 Male 2016 627
TX_CURR Age/Sex: 5-14 Female 2016 3,160
TX_CURR Age/Sex: 5-14 Male 2016 3,179
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 86,220
TX_CURR Sum of age/sex disaggregates 2016 86,220
TX_NEW Breastfeeding status 2016 1,338
TX_NEW By Age/Sex: <1 Female 2016 251
TX_NEW By Age/Sex: <1 Male 2016 229
TX_NEW By Age/Sex: 1-4 Female 2016 486
TX_NEW By Age/Sex: 1-4 Male 2016 547
TX_NEW By Age/Sex: 10-14 Female 2016 392
TX_NEW By Age/Sex: 10-14 Male 2016 332
TX_NEW By Age/Sex: 15-19 Female 2016 535
TX_NEW By Age/Sex: 15-19 Male 2016 148
TX_NEW By Age/Sex: 20-24 Female 2016 2,017
TX_NEW By Age/Sex: 20-24 Male 2016 253
TX_NEW By Age/Sex: 25-49 Female 2016 9,435
TX_NEW By Age/Sex: 25-49 Male 2016 5,514
TX_NEW By Age/Sex: 5-9 Female 2016 378
TX_NEW By Age/Sex: 5-9 Male 2016 447
TX_NEW By Age/Sex: 50+ Female 2016 757
TX_NEW By Age/Sex: 50+ Male 2016 916
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 22,637
TX_NEW Pregnancy status 2016 4,899
TX_NEW Sum of Age/Sex disaggregates 2016 22,637
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 18,110
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 22,637
Cross Cutting Budget Categories and Known Amounts Total: $100,000
Human Resources for Health $50,000
Key Populations: MSM and TG $50,000
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs